MedTrace Logo

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

NCT07521137 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-06-15

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis

Conditions

  • Candidiasis, Vulvovaginal

Interventions

DRUG

OCF001 Intravaginal Gel

OCF001 is an antifungal antibiotic that is formulated in a water-miscible viscous gel at concentrations of 0.150 mg / g of gel.

DRUG

Placebo Gel

Placebo (Gel formulation without OCF)

Sponsors & Collaborators

  • Sano Chemicals Inc

    lead INDUSTRY

Principal Investigators

  • Christina Muzny, MD · UAB Sexual Health Research Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-04
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07521137 on ClinicalTrials.gov